Chronic Kidney Disease Clinical Trial
— CLOCKOfficial title:
Comparison of Effectiveness and Safety of Three Lock Solutions for Long-Term Central Venous Catheter for Hemodialysis
Background: Poor flow (PF) and catheter-related blood stream infections (CRBSI) are highly
prevalent among CKD 5D patients with long-term central venous catheters. Heparin (H)
catheter lock solutions are commonly used to maintain catheter patency, however PF and CRBSI
incidence remains high. The purpose of this study was to evaluate two lock solutions on
reduction of PF and CRBSI: one, a lock solution combining of the tetracycline antibiotic
minocycline with the anticoagulant/chelation agent EDTA (M-EDTA) versus H; and other,
trisodium citrate (C) versus H. M-EDTA and C were also evaluated as to their safety versus
H.
Methods:As regards the pilot project, thirty CKD 5D patients on high-efficiency hemodialysis
(blood flow rate = 350 ml/min) at the Integrated Centre of Nephrology (Guarulhos, Brazil)
were randomized 1:1:1 to receive M-EDTA, C or H locks for 15 weeks. Lock solutions
concentrations were M-EDTA 30 mg/ml/3 mg/ml, C 30% (C) and H 1,000 U/ml and both
investigators and patients were blinded to treatment allocation. The primary end-point was a
10% reduction in HD blood flow rates (35ml). The frequency of CRBSI was recorded. Bleeding
and lock solution-related adverse events were the primary safety end points. Logistic
Regression was performed to evaluate differences in PF rates among the treatments (SPSS
version 13.0, IBM, USA).
Based upon the pilot-study data, the clinical trials has being executed in order to verify
whether the three lock solutions have the same performance or not.
Status | Completed |
Enrollment | 75 |
Est. completion date | March 2016 |
Est. primary completion date | February 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - male and female patients; - patients with subclavian long term central venous catheter; - patients on on high-efficiency hemodialysis (BFR= 350 ml; dialisate flow = 500 ml; 3 times; 4-hour sessions). Exclusion Criteria: - pregnant; patients on oral coagulants; patients aged less than 18 years; - patients aged more than 75 years |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
Brazil | Integrated Centre of Nephrology | Guarulhos | Sao Paulo |
Lead Sponsor | Collaborator |
---|---|
University of Sao Paulo | Fundação de Amparo à Pesquisa do Estado de São Paulo |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Poor Blood Flow Rate(BFR) | Reduction of 35 ml in the BFR of 2350 ml on hemodialysis is considered a primary endpoint for this trial | 100 days | No |
Secondary | Adverse Drug Reactions Related to lock solutions (ADR) | ADR is considered secondary endpoint for this trial | 100 days | Yes |
Secondary | Cather-Related Blood Stream Infection (CRBSI) | CRBSI is considered secondary endpoint for this trials | 100 days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Terminated |
NCT04043026 -
The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
|
||
Completed |
NCT05318014 -
Low-protein Formula Supplements in Chronic Kidney Disease
|
N/A | |
Active, not recruiting |
NCT06071065 -
Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients
|
N/A | |
Completed |
NCT02878317 -
Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
|
||
Not yet recruiting |
NCT06039254 -
Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function
|
Phase 1 | |
Recruiting |
NCT03160326 -
The QUALITY Vets Project: Muscle Quality and Kidney Disease
|
||
Completed |
NCT02836574 -
A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease
|
Phase 2 | |
Completed |
NCT02875886 -
DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Withdrawn |
NCT02885545 -
The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial
|
Phase 4 | |
Completed |
NCT02896309 -
The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity
|
N/A | |
Completed |
NCT02756520 -
Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
|
||
Active, not recruiting |
NCT02483039 -
Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization
|
N/A | |
Completed |
NCT02369549 -
Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease
|
Phase 3 | |
Completed |
NCT02992548 -
Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease
|
Phase 4 | |
Terminated |
NCT02543177 -
Optimised Procedure in Patients With NSTEMI and CKD
|
N/A | |
Recruiting |
NCT02205944 -
Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes
|
N/A | |
Active, not recruiting |
NCT02231138 -
Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease
|
Phase 4 |